Astria Therapeutics, Inc.
ATXSNASDAQHealthcare
$12.58
+$0.00(+0.00%)
Market Cap$718127262
P/E Ratio—
52W High$13.29
52W Low$3.555
Astria Therapeutics, Inc. (ATXS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ATXS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.06B | $0.03B | $0.02B | $0.03B |
| G&A Expenses | $0.03B | $0.03B | $0.02B | $0.01B | $0.01B |
| Total Operating Expenses | $0.11B | $0.08B | $0.05B | $0.19B | $0.04B |
| Operating Income | ($0.11B) | ($0.08B) | ($0.05B) | ($0.19B) | ($0.04B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.02B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.09B) | ($0.07B) | ($0.05B) | ($0.19B) | ($0.04B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.09B) | ($0.07B) | ($0.05B) | ($0.19B) | ($0.04B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.68 | $-2.42 | $-3.55 | $-24.58 | $-12.20 |
| Wtd Avg Shares | 0.06B | 0.03B | 0.01B | 0.01B | 0.00B |
| EBITDA | ($0.11B) | ($0.08B) | ($0.05B) | ($0.03B) | ($0.04B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Astria Therapeutics, Inc. data
About Astria Therapeutics, Inc. (ATXS) Income Statement
Astria Therapeutics, Inc. (ATXS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, ATXS reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.09B) — a net profit margin of —.
Frequently asked questions
ATXS · 4 questionsAstria Therapeutics, Inc. (ATXS) reported revenue of $0.00B for 2024, down —% year-over-year.
ATXS revenueATXS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08